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Abstract: PI3Kγ is a multifaceted protein, crucially involved in cardiovascular and immune systems.
Several studies described the biological and physiological functions of this enzyme in the regulation of
cardiovascular system, while others stressed its role in the modulation of immunity. Although PI3Kγ
has been historically investigated for its role in leukocytes, the last decade of research also dedicated
efforts to explore its functions in the cardiovascular system. In this review, we report an overview
recapitulating how PI3Kγ signaling participates in the regulation of vascular functions involved in
blood pressure regulation. Moreover, we also summarize the main functions of PI3Kγ in immune
responses that could be potentially important in the interaction with the cardiovascular system.
Considering that vascular and immune mechanisms are increasingly emerging as intertwining
players in hypertension, PI3Kγ could be an intriguing pathway acting on both sides. The availability
of specific inhibitors introduces a perspective of further translational research and clinical approaches
that could be exploited in hypertension.
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1. Introduction
Phosphoinositide 3-kinases (PI3Ks) are enzymes that mediate intracellular transduction pathways
by catalyzing the phosphorylation of phosphatidylinositol lipids at the 3-hydroxyl group of the inositol
ring upon several stimuli [1,2]. According to their substrate affinity, they are grouped into three
classes (I–III). Class I PI3Ks catalyzes the formation from phosphatidylinositol-4,5-bisphosphate
(PI-4,5-P2). Class II PI3Ks generates PI-3-P, PI-3,4-P2, and PIP3, and Class III PI3Ks generates
phosphatidylinositol-3-phosphate (PI-3-P) from phosphatidylinositol (PI) [3,4] (Figure 1). Among these,
Class I has been extensively characterized for its role in the cardiovascular and immune systems [5–8].
Belonging to a conserved family, PI3Ks are composed of three domains: the C2 domain, used
to bind membranes, the helical domain with a regulatory function, and the catalytic domain with
kinase activity [1–4]. Class I PI3Ks includes two subfamilies with a conserved regulatory subunit but
differently activated. Class IA PI3Ks is activated by growth factor receptor tyrosine kinases (RTKs),
whereas Class IB PI3Ks is mainly linked to G-protein-coupled receptors (GPCRs) [1–4]. Class IB PI3Ks
has been recognized as a crucial mediator of signaling pathways regulating vascular physiology [4,9,10].
Furthermore, each class is further characterized for comprising different isoforms [1].
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Figure 1. Phosphoinositide 3-kinases (PI3Ks) can be activated upon plasma membrane (PM) 
receptors, tyrosine kinases receptors (RTKs), and G protein-coupled receptors (GPCRs). p110α, p110β, 
and p110 bind directly with phosphotyrosine of RTKs (left); whereas, p110α, p110β, and p110γ are 
activated by GPCRs (right). Both RTKs and GPCRs also activate Ras, which in turn activates p110α, 
p110γ, and p110δ. 
While some isoforms of Class IB like p110α and p110β are ubiquitous, p110γ, as well as p110δ, 
are expressed by specific cells of both cardiovascular and immune systems [1,10–12]. In particular, 
the p110γ isoform has been historically described for regulating leukocytes’ functions [12] and, more 
specifically, in lymphocytes [12]. Indeed, p110γ isoform contributes to the regulation of certain 
processes mediating the recruitment of immune cells to inflammatory sites [6] and appears to be 
involved in pathologies with localized inflammation affecting target organs as kidney and bone 
marrow [13,14]. Currently, PI3Kγ has been shown to be the principal mediator of effector CD8 T cells 
migration into target organs [12]. In this review, we will highlight the relevance of PI3Kγ signaling 
at crossroads between cardiovascular and immune systems. First, we will give an overview of the 
most significant works published on the role of PI3Kγ pathway in cardiovascular diseases (Table 1). 
Furthermore, we will describe several inflammatory processes in which PI3Kγ signaling is deeply 
involved and may be also relevant in hypertension (Table 2). 
Table 1. PI3Kγ involvement in cardiovascular diseases. 
Disease Functions References
Hypertension L-type calcium channels in vascular myocytes [15–17] 
Heart Failure Myocardial contractility; Cardiac remodeling [18–24] 
Atherosclerosis Plaque stability [25,26] 
Diabetic Cardiomyopathy Cardiac remodeling [27] 
Table 2. PI3Kγ functions in inflammatory responses 
Cell Type Functions References
Mast Cells Hystamine release [8,12] 
Neutrophils Inflammatory recruitment; chemoattractant-mediated signal transduction [12,28] 
Leukocytes Inflammatory recruitment [12] 
Thymocyte Thymocyte development [29] 
Myeloid cells Osteoclastogenesis; bone homeostasis [14] 
Lung-Specific Dendritic Cell Development [30] 
Lymphocytes Inflammatory recruitment [12] 
B cell T cell activation [13] 
T cell Activation; migration; differentiation; CD4:CD8 T cells differentiation ratio [31–34] 
Treg Activation [35] 
2. PI3Kγ: A Focus on Their Signaling Pathway in Cardiovascular Disease and Hypertension 
In the last decade, a consistent piece of literature demonstrated the expression of PI3Kγ in 
cardiovascular system cells [5,15,16], as vascular smooth muscle cells (VSMCs) [36]. In this regard, it 
has been shown that PI3Kγ is involved in hypertension [16,17] by regulating vascular function [17] 
and particularly myogenic tone, defined as the physiological behavior of resistance arteries to 
Figure 1. Phosphoinositide 3-kinases (PI3Ks) can be activated upon plasma membrane (PM) receptors,
tyrosine kinases receptors (RTKs), and G protein-coupled receptors (GPCRs). p110α, p110β, and p110
bind directly with phosphotyrosine of RTKs (left); whereas, p110α, p110β, and p110γ are activated by
GPCRs (right). Both RTKs and GPCRs also activate Ras, which in turn activates p110α, p110γ, and p110δ.
While some isoforms of Class IB like p110α and p110β are ubiquitous, p110γ, as well as p110δ,
are expressed by specific cells of both cardiovascular and immune systems [1,10–12]. In particular,
the p110γ isoform has been historically described for regulating leukocytes’ functions [12] and, more
specifically, in lymphocytes [12]. Indeed, p110γ isoform contributes to the regulation of certain
processes mediating the recruitment of immune cells to inflammatory sites [6] and appears to be
involved in pathologies with localized inflammation affecting target organs as kidney and bone
marrow [13,14]. Currently, PI3Kγ has been shown to be the principal mediator of effector CD8 T cells
migration into target organs [12]. In this review, we will highlight the relevance of PI3Kγ signaling
at crossroads between cardiovascular and immune systems. First, we will give an overview of the
most significant works published on the role of PI3Kγ pathway in cardiovascular diseases (Table 1).
Furthermore, we will describe several inflammatory processes in which PI3Kγ signaling is deeply
involved and may be also relevant in hypertension (Table 2).
Table 1. PI3Kγ involvement in cardiovascular diseases.
isease Functions Ref r nces
ypertension L-type calcium channels in vascular myocytes [15–17]
eart Failure yocardial contractili y; Cardiac remodeling [18–24]
Atherosclerosis Plaque stability [25,26]
Diabetic Cardiomyopathy Cardiac remodeling [27]
Table 2. PI3Kγ functions in inflammatory responses
ell ype Functions References
Mast Cells Hystamine release [8,12]
Neutrophils Inflammatory recruitment; chemoattractant-mediated signal transduction [12,28]
Leukocytes Inflammatory recruitment [12]
c t Thymocyte development [29]
l i cells Osteoclastogene is; bone homeosta is [14]
- cific e ritic ell Development [30]
Lymphocytes Inflammatory recruitment [12]
B cell T cell activation [13]
T cell Activation; migration; differentiation; CD4:CD8 T cells differentiation ratio [31–34]
Treg Activation [35]
2. PI3Kγ: A Focus on Their Signaling Pathway in Cardiovascular Disease and Hypertension
In the last decade, a consistent piece of literature demonstrated the expression of PI3Kγ in
cardiovascular system cells [5,15,16], as vascular smooth muscle cells (VSMCs) [36]. In this regard, it
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has been shown that PI3Kγ is involved in hypertension [16,17] by regulating vascular function [17] and
particularly myogenic tone, defined as the physiological behavior of resistance arteries to counteract
perfusion pressure increases and mainly relying on the constrictor tone of VSMCs [17,36–38]. Both in
experimental animal models of hypertension and in hypertensive patients, it was reported that the
increase in peripheral vascular resistances unquestionably contributes to the maintenance of chronic
hypertensive status [37–41]. In response to an elevation of intravascular pressure [36,37], the lumen
diameter of resistance arteries is subjected to a reduction [36], independently of neural control. Thus,
the myogenic response is established as an intrinsic function of VSMCs wall in response to a variety of
stimuli [42–44] and contributes to the process of blood flow autoregulation in tissues [45]. The myogenic
tone is generally described as the sequence of three phases [42]. The first one, also called basal tone, is
characterized by an increased intracellular calcium influx through the L-type voltage gated calcium
channel (LTCC). The second one consists of a simultaneous higher constriction of VSMC to a steady
increase in the intracellular concentration of calcium levels and to a stronger intracellular calcium
sensitization. In the last phase, a significant dilation of the arterial wall occurs due to massive calcium
entry [46].
To date, research on the mechanisms underlying hypertension has been focused on the
involvement of LTCC in VSMCs dysfunction, providing a molecular target to fight the disease [15,16].
It was initially found that PI3Kγ modulates LTCC functions and expression on plasma membranes
of VSMCs through Akt signaling [15,16]. Moreover, PI3Kγ signaling has been shown to be necessary
in the activation of Ca2+ influx in vascular myocytes after stimulation with angiotensin II [47,48].
In past studies, we documented that PI3Kγ, expressed in VSMCs, is crucial to maintaining the balance
between vasoconstriction and vasorelaxation induced by GPCRs agonist angiotensin II [17]. We also
revealed that mice lacking PI3Kγ are protected from hypertension induced by chronic administration
of angiotensin II [16]. Moreover, the absence of PI3Kγ and the expression of a PI3Kγ kinase dead
mutant induce a significant reduction of the LTTCs influx and a reduced contractility of vessels upon
angiotensin II stimulation [16]. Particularly, we also found that PI3Kγ is able to induce calcium influx
through phosphorylation of the LTCC Cavβ2a subunit by an Akt consensus site [16]. This finding
is strongly correlated with our previous data that demonstrated how the expression of a dominant
negative PKB/Akt mutant in vessels reduces the vasoconstriction after angiotensin II exposures [17].
At the same time, both the inhibition of kinase-dependent PI3Kγ signaling and its intracellular signaling
mediated by Akt impair vascular myogenic tone [16].
Beyond its relevance in the regulation of angiotensin II-induced L-type-dependent Ca2+ influx,
PI3Kγ signaling has also been demonstrated as a crucial regulator of oxidative stress in vascular tissues
of mice infused with angiotensin II [17]. Considering that myogenic tone and oxidative stress have been
historically linked [39], it is conceivable that PI3Kγ plays an additional role in vascular inflammatory
responses in hypertension [16]. On this latter note, it is now clearly evident that hypertension is also
characterized by immune cells infiltration in peripheral target organs. We and others have observed
a significant early infiltration of immune cells in hypertensive mice aorta and kidneys, as well as an
enhancement of the costimulation pathway, necessary for the activation and egression of T cells and
provided by antigen-presenting cells (APCs) [41,49,50]. Nevertheless, how this process is activated in
hypertension remains still partially unfolded. Early studies showed that CD28 binding to B7-1 and
B7-2 ligands on APCs mediates costimulation and is activated by PI3Ks [31]. Thus, the isoform p110γ
could acquire outstanding relevance in the investigation of molecular mechanisms underlying T cell
mobilization in hypertension.
Furthermore, PI3Kγ signaling has also been shown to be involved in other mechanisms related
to vascular function, since the activation of Akt can alternatively promote the target blockade
through glycogen synthase kinase 3 (GSK-3β) [51]. GSK-3β, in turn, phosphorylates several proteins,
maintaining their inactive state and promoting their degradation. Furthermore, Akt is involved in the
control of vascular tone through phosphorylating and activating the nitric oxide synthase NOS3 [52],
promoting angiogenesis and regulating vascular homeostasis [53]. When its signaling is mediated by
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phosphatases SHIP1 and SHIP2, as is the Phosphatase and tensin homolog (PTEN), PI3Ks have the
opposite action [18,19,54,55]. PTEN mainly has a PDZ domain inhibiting the PI3K-mediated activation
of PKB [55].
A last aspect deserving attention is a peculiarity of PI3Kγ that has a dual function [20]:
a kinase-dependent activity that positively regulates Akt signaling [16] and a kinase-independent
activity that reduces the cAMP levels through PDE3B [20–24]. Recently, we asserted the importance
of their kinase-independent activity in the integrity of synaptic plasticity and noradrenergic neurons
transmission of locus coeruleus (LC), providing an unpredictable role for PI3Kγ in the neuronal
excitability of LC [56]. Changes in PI3Kγ expression and modulations of the downstream pathway
have been investigated as potential therapeutic targets in several pathologies affecting the vascular
system, the neuronal system, and, more interestingly, immune disorders [9,25,27,57,58].
The genetic ablation of the p110γ subunit or that carry a kinase-death form of PI3Kγ allows
for the dissection of molecular mechanisms undergoing immune cell activation in cardiovascular
diseases [16,17,27]. In inflamed lesions, p110γ is required for the activation of Akt pathway
kinase-dependent in macrophages in response to angiotensin II both in vitro and in vivo, suggesting
a possible target to fight atherosclerosis in mice [26,59]. Furthermore, angiotensin II signaling,
which promotes oxidative stress and plaque deterioration [59], is markedly reduced in p110γ-null
macrophages [20]. In view of these data, the proposal of PI3Kγ as a link between the angiotensin II
pathway and the immune responses in atherosclerosis and probably in hypertension is convincing.
These data were partially confirmed when it was demonstrated that PI3Kγ signaling was involved in
the regulation of vascular myogenic tone [16].
Although our past data have added further knowledge on the mechanisms regulating myogenic
tone in resistance arteries, by modifying the LTCCs, it still remains unclear how the activation of
immune cells in hypertension induced by angiotensin II is established.
3. PI3Kγ in Immunity
Upon agonists of GPCRs, p110γ-deficient mice display a compromised response of both immune
and inflammatory cells [29,60], confirming the crucial role of the p110γ isoform in the activation of
those cells participating in a wide variety of inflammatory processes (Figure 2). It was found that
mice lacking p110γ show an impaired neutrophil chemotaxis simultaneously to a reduced thymocyte
survival and to T cells activation [29,60]. Indeed, the p110γ catalytic subunit is required for a correct
T cell development of secondary lymphoid organs [25]. Additionally, in a murine model of septic
peritonitis, macrophages from PI3Kγ−/− mice accumulated in inflamed organs worsen the evolution
of the disease [60]. In PI3Kγ−/− mice, PIP3 is not effectively produced by neutrophils and the
downstream pathway is inhibited; thus, motility dysfunction occurs and the inflammatory response is
defective [32,60]. Evidence attesting the importance of PI3Kγ in the regulation of immune responses
come from studies in mice that have a genetic ablation of PI3Kγ or that carry a kinase-death form of
the proteins that are particularly suitable to explore the activation and differentiation of T cells into an
activated phenotype. PI3KγKD/KD mice display a dysfunction of the complex TCR/CD28-mediated
CD4 and CD8 T cells activation and, especially, a deficiency in CD4 T cells differentiation toward
activated Th1, Th2, Th17, and Treg [33]. Indeed, PI3Kγ signaling seems to be indispensable for normal
T cells functions.
However, neonatal mice lacking the p110γ isoform exhibit a reduced CD4 cell differentiation
and an augmented CD8 cell generation, compromising the CD4:CD8 cell ratio [34]. A CD4:CD8
ratio dysfunction could exacerbate an optimal immune response and could hamper a functional
thymus growth [35]. In a murine model of inflammatory peritonitis, wild-type mice have a normal
migration of naïve T cells, whereas p110γ deficiency mice display a decrease in effector CD8 T cells
into inflamed organ, without affecting their proliferation or differentiation [28,32]. Thus, PI3Kγ can
differently direct multifaceted roles according to the type of cells in which it is expressed and to the
pathophysiological context.
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Figure 2. Representation of the main signalings in immune cells. Upon G protein-coupled receptors 
(GPCRs), PI3Kγ catalyzes the PIP3 formation from PIP2. PIP3 binds target proteins, as Akt and PDK1, 
with PH domains activating intracellular pathways, as development and maintenance through  
m-TOR and as survival and proliferation through PKB. PIP3 can also mediate protein degradation 
through GSK-3β signaling. PTEN can inhibit PI3Kγ signaling through PIP3 dephosphorylation. 
At present, the molecular mechanism of T cells activation in hypertension remains unclear, which 
makes the possibility of further exploring the role of PI3Kγ signaling in T cells during hypertensive 
challenges appealing. Indeed, mounting evidence reveals that immune cells are essential to the onset of 
hypertension induced by angiotensin II or upon DOCA-salt treatment [41,49,61], infiltrating target 
organs and, more intriguingly, that mice lacking lymphocytes are protected from increased blood 
pressure [41,49]. More recent data suggest that an oligoclonal population of CD8 T cells is able to 
decrease the number and size of small blood vessels in the kidney, causing a retention of salt and water 
and contributing to high blood pressure [62]. The CD86 activation in splenic macrophages, upon 
angiotensin II, localized in the marginal zone of the spleen, is essential to enhance the T cells egression 
and consequent infiltration into aorta and kidneys [41,49]. These data suggest that a crosstalk between 
the innate and adaptive immunity is necessary for the onset of hypertension. Furthermore, CD86 is one 
of the surface markers of maturation towards APCs, mediating the costimulation pathway [63]. We 
demonstrated that placental growth factor (PlGF) is a crucial player of this pathway [49], thus 
suggesting that, even the interaction between this signaling pathway and PI3Kγ could be investigated 
in search of mechanisms that couple vascular and immune alterations contributing to hypertension. 
Thus, in experimental settings of hypertension, it could be particularly interesting to investigate 
the role of PI3Kγ signaling in regulating the activation of CD8 T cells into effector cells. It is important 
to notice that more recent data investigated other immune functions of PI3Kγ, revealing the existence 
of an alternative mechanism involved in adaptive immunity activation and dependent on the 
expression of PI3Kγ in dendritic cells (DCs). Indeed, it was reported that PI3Kγ is required in DC 
maturation [30]. Particularly, the Ras-PI3Kγ-Akt-mTOR pathway has been shown to be essential for 
the development of lung DCs [30], suggesting a specific tissue–organ role for PI3Kγ signaling.  
This latter report suggests that an even more unpredictable complexity could be explored  
when approaching PI3Kγ signaling in cardiovascular diseases and, particularly, hypertension,  
where an interaction between vascular and immune systems emerges as a main regulator of blood 
pressure increases. 
4. Conclusions and Perspectives 
We have previously found that PI3Kγ is a crucial player in the control of blood pressure  
levels [16,17,57]. On the one hand, PI3Kγ−/− mice are protected from hypertension by a reduction of 
Figure 2. Representation of the main signalings in immune cells. Upon G protein-coupled receptors
(GPCRs), PI3Kγ catalyzes the PIP3 formation from PIP2. PIP3 binds target proteins, as Akt and PDK1,
with PH domains activating intracellular pathways, as development and maintenance through m-TOR
and as survival and proliferation through PKB. PIP3 can also mediate protein degradation through
GSK-3β signaling. PTEN can inhibit PI3Kγ signaling through PIP3 dephosphorylation.
At present, the molecular mechanism of T cells activation in hypertension remains unclear, which
makes the possibility of further exploring the role of PI3Kγ signaling in T cells during hypertensive
challenges appealing. Indeed, mounting evidence reveals that immune cells are essential to the onset
of hypertension induced by angiotensin II or upon DOCA-salt treatment [41,49,61], infiltrating target
organs and, more intriguingly, that mice lacking lymphocytes re protected from increased blood
pressure [41,49]. More recent data suggest that an oligoclonal populatio of CD8 T cells is able to
decrease the number an size of small blood vessels i th kidney, causi g a retention of salt and
water and contributing to high blood pressure [62]. The CD86 activation in splenic macrophages, upon
angiotensin II, localized in the marginal zone of the spleen, is essential to enhance the T cells egression
and consequent infiltration into aorta and kidneys [41,49]. These data suggest that a crosstalk between
the innate and adaptive immunity is necessary for the onset of hypertension. Furthermore, CD86 is
one of the surface markers of maturation towards APCs, mediating the costimulation pathway [63].
We demonstrated that placental growth factor (PlGF) is a crucial player of this pathway [49], thus
suggesting that, even the interaction between this sig aling pathway and PI3Kγ could be investigated
in search of mechanisms that couple vascular and immune alterati ns contributing to hypertension.
Thus, in experimental settings of hypertension, it could be particularly interesting to i vestigate
the role of PI3Kγ signaling in regulating the activation of CD8 T cells into effector cells. It is important
to notice that more recent data investigated other immune functions of PI3Kγ, revealing the existence of
an alternative mechanism involved in adaptive immunity activation and dependent on the expression
of PI3Kγ in dendritic cells (DCs). Indeed, it was reported that PI3Kγ is required in DC maturation [30].
Particularly, the Ras-PI3Kγ-Akt-mTOR pathway has been shown to be essential for the development of
lung DCs [30], suggesting a specific tissue–organ role for PI3Kγ signaling. This latter report suggests
that an even more unpredictable complexity could be explored when approaching PI3Kγ signaling in
cardiovascular diseases and, particularly, hypertension, where an interaction between vascular and
immune systems emerges as a main regulator of blood pressure increases.
4. Conclusions and Perspectives
We have previously found that PI3Kγ is a crucial player in the control of blood pressure
levels [16,17,57]. On the one hand, PI3Kγ−/− mice are protected from hypertension by a reduction of
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peripheral resistances [16], and this effect, in the angiotensin II hypertension model, has been observed
simultaneously to reduce inflammatory response in vascular tissues [17]. In this scenario, PI3Kγ could
be a possible mediator of the intricate crosstalk that also modulates functions of T cells, which are now
well known to play a determinant role in the onset of hypertension and in related target organ damage.
It is demanding to investigate novel roles of PI3Kγ in the immune mechanisms related to
hypertension, and it will be instrumental to have a more complete knowledge of how a multifaceted
signaling pathway could play different roles in the mechanisms regulating blood pressure.
Furthermore, the development of selective inhibitors could help to elucidate distinct biological
processes in which PI3Kγ is involved and to identify potential targets of a wide variety of pathologies
affecting the cardiovascular system. In our laboratory, we found that a novel molecule, GE21, blocks the
kinase-dependent signaling of PI3Kγ and has an antihypertensive effect in mice [16]. More recently, we
have described that GE21 also has a protective functional role in diabetic cardiomyopathy, associated to
a decrease in inflammation and fibrosis [27]. GE21 administrated in a dose-dependent manner is able
to preserve cardiac function. The possibility to further test the pharmacological inhibition of PI3Kγ
signaling to approach immune mechanisms in hypertension is the translational step forward that could
contribute to the growing research area for therapeutic applications of PI3Kγ inhibitors [16,27,64].
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